# KalVista Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kalvista-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.kalvista.com
- Total disclosed funding: $46M
- Latest round: Series B (Jul 22, 2015)
- Investors on record: 5

## About

Founded in 2011 and based in Massachusetts, US, KalVista Pharmaceuticals, Inc. is a biotechnology company that focuses on developing pharmaceuticals based on small molecule protease and plasma kallikrein inhibitors to provide prophylactic therapeutics. CEO Andrew Crockett, Edward Feener, Lloyd Aiello, and Robert Haigh co-founded the company and raised USD 46.2 million in two venture financings from private equity investors, including SV Health Investors, RA Capital, and Venrock. In June 2016, KalVista Pharmaceuticals, Inc. merged with Carbylan Therapeutics, Inc. to operate as KalVista Pharmaceuticals, Inc. Following the merger, the company became publicly listed on the Nasdaq under the ticker symbol KALV.

The company's R&D team provides protease and plasma kallikrein inhibitors with multiple small molecules to treat diabetes-related blindness by reducing retinal vessel leakage and suppressing the excessive bradykinin production for patients with acute HAE (hereditary angioedema) and DME (diabetic macular edema). The company's drug candidates portfolio includes KVD900, KVD824, KVD001, Factor XIIa, and Oral DME Molecules.

KalVista Pharmaceuticals, Inc. had a -21.33 percent decrease in generated revenue with USD 12.69 million in FY 2020 and USD 16.13 million in FY 2019.

KalVista Pharmaceuticals, Inc. plans to fund the planned Phase 3 trial of KVD900, Phase 2 trial of KVD824, and the continued development of Factor XIIa programs following the February 2021 public offering.

## Funding rounds

- Series B, Jul 22, 2015, $33M — Venrock, SV Health Investors, Novo Holdings, Longwood Fund, RA Capital Management
- Series A, Aug 23, 2011, $13M — SV Health Investors, Novo Holdings

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A, Series B
- Novo Holdings — Series A, Series B
- Venrock (https://capitalatlas.ai/funds/venrock) — Series B
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B